Flexion Therapeutics (FLXN) Announces Zilretta Trial in T2D Patients with Knee OA Met Primary Endpoint
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Flexion Therapeutics Reports Primary Endpoint Met in Clinical Trial Evaluating Investigational Drug Candidate Zilrettaâ„¢ in Type 2 Diabetes Patients with Knee Osteoarthritis
November 1, 2016 7:00 AM EDT-  Results Demonstrate a Markedly Lower Rise in Blood Glucose in Patients Receiving a Zilretta Injection Compared to Patients Receiving an Immediate- Release Triamcinolone Acetonide Injection  -
-  Difference was Both Statistically Significant and Clinically Relevant  -
- Â Conference Call Scheduled... More